Citadel Advisors’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-30,684
Closed -$26K 10679
2019
Q4
$26K Buy
+30,684
New +$23.6K ﹤0.01% 8904
2019
Q3
Sell
-134,965
Closed -$70K 10255
2019
Q2
$70K Sell
134,965
-87,250
-39% -$43.6K ﹤0.01% 8640
2019
Q1
$100K Buy
222,215
+208,000
+1,463% +$97.1K ﹤0.01% 8561
2018
Q4
$7K Sell
14,215
-46,593
-77% -$23.1K ﹤0.01% 8973
2018
Q3
$34K Buy
60,808
+50,544
+492% +$27.1K ﹤0.01% 8902
2018
Q2
$5K Buy
+10,264
New +$4.78K ﹤0.01% 8739
2018
Q1
Sell
-76,245
Closed -$29K 9303
2017
Q4
$29K Sell
76,245
-11,166
-13% -$4.24K ﹤0.01% 7775
2017
Q3
$31K Buy
87,411
+35,670
+69% +$13.2K ﹤0.01% 7286
2017
Q2
$20K Buy
51,741
+6,941
+15% +$2.83K ﹤0.01% 7300
2017
Q1
$20K Sell
44,800
-10,927
-20% -$4.8K ﹤0.01% 7254
2016
Q4
$21K Sell
55,727
-19,919
-26% -$6.74K ﹤0.01% 7084
2016
Q3
$20K Buy
75,646
+14,913
+25% +$3.78K ﹤0.01% 7062
2016
Q2
$15K Buy
+60,733
New +$10.4K ﹤0.01% 6694
2016
Q1
Sell
-271,701
Closed -$31K 9367
2015
Q4
$31K Buy
271,701
+103,217
+61% +$14.6K ﹤0.01% 7665
2015
Q3
$32K Buy
168,484
+98,879
+142% +$33.6K ﹤0.01% 7892
2015
Q2
$49K Buy
69,605
+20,451
+42% +$14.1K ﹤0.01% 7676
2015
Q1
$33K Buy
49,154
+31,214
+174% +$21.8K ﹤0.01% 7654
2014
Q4
$14K Sell
17,940
-12,079
-40% -$8.25K ﹤0.01% 8026
2014
Q3
$14K Sell
30,019
-11,669
-28% -$5.66K ﹤0.01% 7667
2014
Q2
$21K Sell
41,688
-142,961
-77% -$69.1K ﹤0.01% 7272
2014
Q1
$59K Buy
+184,649
New +$68.6K ﹤0.01% 6644

Citadel Advisors's GCVRZ Position: Q1 2020 in Review

Citadel Advisors sold out of Sanofi Contingent Value Rights (GCVRZ) in Q1 2020, closing a stake of 30,684 shares — an estimated $26K sold.

Citadel Advisors first reported a position in GCVRZ in Q1 2014 and held it in 21 quarters. The position peaked at $100K in Q1 2019. 2 funds tracked by Wall St. Rank hold GCVRZ as of Q1 2020.

  • Citadel Advisors reported no remaining Sanofi Contingent Value Rights position as of Q1 2020 after selling out during the quarter.
  • Citadel Advisors sold 30,684 Sanofi Contingent Value Rights shares in Q1 2020, an estimated $26K.
  • Citadel Advisors first reported a position in Sanofi Contingent Value Rights in Q1 2014 and held it in 21 quarters.
  • Citadel Advisors's Sanofi Contingent Value Rights position peaked at $100K in Q1 2019.
  • 2 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q1 2020.

Based on Citadel Advisors's 13F filing for Q1 2020, filed 15 May 2020.